The global continuous glucose monitoring systems market size reached USD 7.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 10.9 Billion by 2033, exhibiting a growth rate (CAGR) of 4.75% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 7.0 Billion |
Market Forecast in 2033
|
USD 10.9 Billion |
Market Growth Rate 2025-2033 | 4.75% |
Continuous glucose monitoring systems (CGMS) are technologically advanced devices that automatically track blood glucose levels. They consist of a transmitter-integrated sensor that functions through a transcutaneous or subcutaneous route to continuously measure the glucose concentration in interstitial fluid. The transmitter then sends the information to a wireless monitor that can be clipped to clothes. Continuous glucose monitoring systems assist in providing a complete profile of diabetes, alerting highs and lows of blood sugar levels, detecting patterns, and increasing patient insights regarding physical activity, medication choices, food portions and stress. As compared to conventional glucose monitoring devices, CGMS are prick-free as they can be placed over the skin, thus aiding in providing real-time information in a quick and painless fashion.
The rising geriatric population across the globe that are more susceptible to developing diabetes is creating a positive outlook for the market. CGMS is commonly used for measuring glucose and insulin level in the body, which further sounds an alarm if it drops or rises to a dangerous level. In line with this, the widespread product utilization to identify hypoglycemia and hyperglycemic situations in real-time is favoring the market growth. Moreover, significant improvements and new technological advancements in CGMS that aid in detecting glycated hemoglobin (Hb1ac) in patients with diabetes are providing a considerable boost to the market growth. Additionally, the integration of artificial pancreas device systems with CGMS technology to pump insulin and administer optimum dosage to manage the blood sugar levels of patients is positively impacting the market growth. Apart from this, the introduction of non-invasive CGMS devices as a convenient alternative, extensive research and development (R&D) activities and the increasing demand for less or minimally invasive diagnostic tools are anticipated to drive the market further toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global continuous glucose monitoring systems market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on component, demographics and end user.
Breakup by Component:
Breakup by Demographics:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc. and Waveform Technologies Inc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Component, Demographics, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc. and Waveform Technologies Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global continuous glucose monitoring systems market was valued at USD 7.0 Billion in 2024.
We expect the global continuous glucose monitoring systems market to exhibit a CAGR of 4.75% during 2025-2033.
The sudden outbreak of the COVID-19 pandemic has led to the growing demand for remote monitoring devices, such as continuous glucose monitoring systems to continuously monitor the coronavirus-infected patients with diabetes.
The rising adoption of continuous glucose monitoring systems for measuring glucose and insulin level in the body, as they are non-invasive and provide real-time information, is primarily driving the global continuous glucose monitoring systems market.
Based on the component, the global continuous glucose monitoring systems market can be segmented into sensors, transmitters and receivers, and integrated insulin pumps. Among these, sensors hold the majority of the total market share.
Based on the demographics, the global continuous glucose monitoring systems market has been divided into child population (≤14 years) and adult population (>14 years), where adult population (>14 years) currently exhibits a clear dominance in the market.
Based on the end user, the global continuous glucose monitoring systems market can be categorized into clinics and diagnostics centers, ICUs, and home healthcare. Currently, home healthcare accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global continuous glucose monitoring systems market include A. Menarini Diagnostics S.r.l., Abbott Laboratories, DexCom Inc., F. Hoffmann-La Roche AG, Glysens Incorporated, LifeScan Inc. (Johnson & Johnson), Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, Senseonics Holdings Inc., and Waveform Technologies Inc.